Advertisement
Organisation › Details
iOnctura S.A.
iOnctura BV, headquartered in Geneva, Switzerland, was founded in June 2017 as a spin out from Merckand funded by M Ventures. It is a clinical stage biotechnology company developing a pipeline of next generation, differentiated molecules that are at the forefront of pioneering new therapies for the treatment of cancer. Each of iOnctura’s programs harness the combined effect of immune-mediated and direct anti-tumour activity and aim to deliver molecules with superior clinical efficacy and safety in oncology. The company’s lead program, IOA-244, will enter the clinic in Q1 2020. The study is aimed to clinically demonstrate for the first time that a highly selective PI3Kd inhibition not only drives an immunemediated response but also a direct anti-tumoural effect in a stratified patient population across multiple solid tumour indications. The Company’s second molecule is a novel autotaxin (ATX) inhibitor at IND stage for patients with solid tumours burdened with cancer-associated fibrosis. *
Start | 2017-06-20 established (s-off) | |
Group | iOnctura (Group) | |
Predecessor | Merck KGaA | |
Industry | cancer immunotherapy (immuno-oncology, I-O) | |
Industry 2 | drug development | |
Person | Pickering, Catherine (iOnctura 201706– CEO + Co-Founder before Merck Head Global Oncology Licensing + BusDev) | |
Region | Genève (Geneva) GE | |
Country | Switzerland | |
Street | 15 Avenue Sécheron Campus Biotech Innovation Park, Bâtiment F2 | |
City | 1202 Genève GE | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: iOnctura B.V.. (1/23/20). "Press Release: iOnctura Raises EUR 15 Million in Series A Financing to Progress Its Pipeline into Clinical Development". Amsterdam. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for iOnctura (Group)
- [1] iOnctura S.A.. (7/14/20). "Press Release: iOnctura Extends Series A to EUR 20.1m". Geneva....
- [2] iOnctura B.V.. (1/23/20). "Press Release: iOnctura Raises EUR 15 Million in Series A Financing to Progress Its Pipeline into Clinical Development". Amsterdam....
- [3] iOnctura S.A.. (3/12/19). "Press Release: iOnctura Bolsters Management Team with Senior Appointments. Michael Lahn Appointed Chief Medical Officer – Zoë Johnson Appointed Chief Scientific Officer". Geneva....
- [4] iOnctura S.A.. (2/28/19). "Press Release: iOnctura Selected for an Oral Presentation at 2019 AACR Annual Meeting". Geneva....
- [5] iOnctura S.A.. (11/28/17). "Press Release: iOnctura Announces Appointment of Leading International Scientific Advisory Board". Geneva....
- [6] Merck KGaA. (6/20/17). "Press Release: Merck Ventures Creates New Immuno-Oncology Company iOnctura". Darmstadt....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top